LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

Company Overview - LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [5] - The company is advancing its lead product candidate, LB-102, which aims to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States [5] - LB-102 is positioned to potentially become a mainstay in psychiatric practice, offering an alternative to existing branded and generic therapeutics [5] Initial Public Offering (IPO) Details - LB Pharmaceuticals announced the pricing of its upsized initial public offering of 19,000,000 shares at a public offering price of $15.00 per share, expecting gross proceeds of $285.0 million before expenses [1] - The offering includes a 30-day option for underwriters to purchase an additional 2,850,000 shares at the initial public offering price [1] - Shares are set to begin trading on the Nasdaq Global Market under the ticker symbol "LBRX" on September 11, 2025, with the offering expected to close on September 12, 2025 [2] Regulatory and Compliance Information - A registration statement on Form S-1 has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 10, 2025 [3] - The offering is being conducted only through a written prospectus, with copies available from the joint bookrunning managers [3]